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effects of probiotics in multiple sclerosis: a
systematic review
Mohammad Morshedi1*† , Reza Hashemi1†, Sara Moazzen2, Amirhossein Sahebkar3,4,5 and
Elaheh-Sadat Hosseinifard1
Abstract
Multiple sclerosis (MS) is an inflammatory and autoimmune neurological disorder which leads to demyelination.
Although the etiology of MS is yet to be known, it appears that regulating the immune system and suppressing
inflammatory pathways may possibly have a favorable effect on the healing of this disease. Evidence suggests that
probiotics consumption via gut microbiome alteration devises beneficial effects in improving immune and
inflammatory responses in MS. All articles were systematically searched (in the main databases) for this paper.
Two investigators independently scrutinized full texts of the potentially eligible articles. The quality of the
study was evaluated using standardized tools. The methodological quality of seven studies included in this
review ranged from fair to good. The findings illustrated that there were statistically significant improvements
in the static and dynamic balance in patients and animals with MS. In the paper in hand, the effects of
probiotics administration on immune and inflammatory markers in MS disease are evaluated. In addition, the
limitations and knowledge gaps were reported while proposing a possible mechanism of probiotics therapy
in modulating immune and inflammatory responses. This systematic review indicated that the probiotics
could improve immune and inflammatory parameters, the cytokines and cells in MS disease. Probiotics may
have efficient effects in management and treatment of MS. More studies are required to clarify the effect of
supplementation with probiotics and their mechanisms in MS disease.
Keywords: Probiotics, Autoimmune diseases, Microbiome, Gut-brain axis, Gut microbiota, Multiple sclerosis,
Immune/inflammatory response, Systematic review
Background
Multiple sclerosis (MS) is considered to be a distinguished
inflammatory, demyelinating and autoimmune neurological
disorder affecting 2.5 million people worldwide [1]. Fre-
quently observed symptoms are numbness, fatigue, vision
loss, dizziness, cognitive defects, depression, and bowel dys-
function [1–4]. MS risk factors can be categorized into two
types: genetic and environmental [1]. The key factors initi-
ating MS, for the most part, continue to remain unknown
[1, 5, 6]. MS pathology is characterized by an increase in
inflammatory responses, destruction of myelin sheaths, pro-
liferation of astrocytes, microglia activation, gliosis, and
axonal degeneration [7, 8]. Additionally, numerous studies
have confirmed that MS is an immune-mediated and
inflammatory disease in which the myelin of the nerve cells
is attacked by the immune system and mediated by the
cluster of differentiation 4 (CD4) myelin-reactive T-helper
1 (Th1) cells [9–14]. Evidence has suggested that inflamma-
tion leads to degeneration of brain axons and neurons in
people with MS. Anti-inflammatory and immunomodula-
tory treatments can prevent or delay the progression of the
MS [11, 14–17]. Findings reveal that the gut microbiome
may well have a notable role in the immune system regula-
tion and exerting anti-inflammatory, antioxidant, and meta-
bolic effects in the host [14, 18–21]. The latter suggests that
targeting gut microbiome might be a crucial target for
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prevention, management, and control of the inflammatory
and autoimmune diseases [22–25].
Evidences are accumulating to suggest that there is a
bidirectional relationship between the intestine and the
central nervous system (CNS), which is called the gut-brain
axis [26]. Moreover, studies reported that alteration of the
gut microbiome could influence inflammatory responses in
human beings and animals with MS [23, 27, 28]. In this
regard, Hoogen et al. [29] indicated that there was an inter-
esting role of diet and gut microbiome in the modulation of
immune diseases. Furthermore, this study determined
whether MS could be treated via modification of gut micro-
biota and probiotics administration. On the other hand,
Probiotics could have favorable effects on the host as func-
tional food and good microorganisms [18] through
normalization of the imbalance gut microbiome [30–32]. In
addition, numerous studies have publicized that the use of
probiotics could improve immune/inflammatory processes
in some diseases such as type 2 diabetes [21], inflammatory
bowel disease (IBD) [33], and neuroinflammatory disorders
[34, 35]. In addition, some studies have exposed that pro-
biotics intake could perform an efficient role in MS disease
[35, 36]. Lactobacilli and Bifidobacteria are of the most
common probiotics, which possess substantial health-
promoting properties such as modulating the population
and composition of gut microbiome and improving
intestinal barrier function [21, 37, 38]. Furthermore, these
microorganisms facilitate the production of metabolic pa-
rameters such as short-chain fatty acids (SCFAs) [39, 40]
and reduce gut permeability [41], which ultimately leads to
improved immune responses and decreased inflammation
[21, 42, 43]. Effects of probiotics on MS are more com-
monly assessed in animal studies. Recently, a pilot study
demonstrated that probiotics (VSL3) administration was as-
sociated with host immune system. Alteration of gut micro-
bial composition by VSL3 supplementation had beneficial
effects on the immune and inflammatory responses in pa-
tients with MS [44]. The mechanisms of the effects of pro-
biotics administration on various features of MS are still
largely undefined and require further investigation.
In this systematic review, the attempts were to evaluate
the effects of probiotics consumption on human and ani-
mal models of MS and explore the mechanisms of effect-
iveness with a particular focus on the immune function
and inflammation.
Methods
The study was performed according to the recommenda-
tions of the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) statement [45]. The
systematic review was registered in PROSPERO, an
international prospective register of systematic reviews
(registration number, CRD42018086594).
Search methods for identification of studies
PubMed, the Cochrane Central Register of Controlled Trials
(CENTRAL), Scopus, EMBASE, Web of Science, Google
Scholar, and reference lists of retrieved articles (prior to De-
cember 24, 2018) were systematically searched for the vari-
ous combinations of the following terms: (Multiple Sclerosis
or MS or Experimental Autoimmune Encephalomyelitis
(EAE) or EAE or Auto-Immune Disease or Autoimmune
Disorder) and (Lactobacillus or Lactobacillales or Probiotics
or Lactobacilli or Lactic Acid Bacteria or Probiotic or Bifido-
bacteria or Bifidobacterium). The Cochrane Library and
databases (included in this review) were searched to ensure
there were no other systematic reviews on this topic.
Inclusion criteria
Inclusion criteria: (1) all article written in English lan-
guage; (2) interventional studies including RCTs and ex-
perimental studies, which assessed the effects of
probiotics administration on immune or/and inflamma-
tory markers in MS patients or animal models of MS
(EAE); (3) studies on individuals diagnosed with MS; (4)
studies reporting the association between probiotic in-
take and immune and inflammatory response. Also, the
full text of potentially eligible articles was scrutinized in-
dependently by two investigators.
Outcome measures
Safety and tolerability outcomes included the proportion of
patients who experienced any treatment-emergent adverse
events (AEs), those withdrawn from the treatment for AEs,
and those experienced any of the following: agitation, anx-
iety, cutaneous rash, diarrhea, dysgeusia, edema, euphoria,
fatigue, gastric pyrosis, headache, hiccup, hot flashes, hyper-
tension, insomnia, nausea, palpitations, and vomiting. Avail-
able data on pharmacological bioavailability were extracted.
Data extraction and quality assessment
The trials and animal studies were independently assessed
by three authors for inclusion and the gained information
from included trials were extracted by them as well, and, in
the case of discrepancies, the final decision was made by a
third investigator or by consensus. Studies were assessed
based on the Population, Intervention, Comparators, Out-
comes, Timing/Setting (PICOTS) framework [46]. Relevant
outcomes including sample characteristics (region, popula-
tion, age, gender), intervention characteristics (probiotic
species and strains, duration of intervention, dose), and spe-
cific results (all immune and inflammatory markers) were
extracted from the selected articles. The study quality and
the risk of bias were critically evaluated using a standard-
ized tool, which was the Cochrane Risk of Bias Tool to
Agency for Healthcare Research and Quality (AHRQ) Stan-
dards and SYRCLE’s tool was used for assessing risk of bias
for animal studies (Additional file 1) [47–49]. From each
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eligible article, the first author, journal, year of publi-
cation, reported risk factors, and number of studies




A total of 4650 articles were initially retrieved as
shown in Fig. 1. Three thousand nine hundred five ci-
tations remained after duplicate studies were excluded
(745). According to mentioned reasons, 745 articles
were deemed ineligible and were subsequently re-
moved. Then, the titles and abstracts of the remaining
articles were reviewed and 114 studies were deemed
to be potentially eligible (3791 articles were excluded).
After reviewing the full texts of the 15 candidate arti-
cles, seven eligible articles (2 RCTs and 5 animal
studies) were finally included for the present system-
atic review.
Study characteristics
Two RCTs and five animal studies were published in Eng-
lish language journals during February 2010 to January
2019. Three studies were carried out in Iran [35, 50], one
in France [51], one in Japan [52], one in the Republic of
Korea [53], and another in Sweden [54]. A summary of the
Fig. 1 Collection of studies for inclusion in systematic review
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study features and major results are depicted in Table 1.
Both human studies were randomized, double-blinded, and
placebo-controlled trial. Participants were all relapsing–re-
mitting MS (RRMS) and identified according to McDonald
criteria and an expanded disability status scale (EDSS)
score ≤ 4.5, in the range age of 18–60 years with a majority
of female participants, by 75–83%. The total number of
individuals was in the range of 48–60. Whilst in animal
studies, the female and male Myelin Oligodendrocyte
Glycoprotein (MOG)-induced EAE in C57BL/6, C57/BL6J,
and PLP (Proteolipid protein)-induced EAE in SJL/J mice
were applied in the range age and number of 7–12 weeks
and 20–70 odds, respectively. The intervention obtained
probiotics including L. plantarum (n = 2) [35, 54], B. ani-
malis (n = 1) [35], E. coli Nissle (n = 1) and archetypal (n =
1) [51], L. casei (n = 3) [50, 52], IRT5 (n = 1) [53], L. para-
casei, L. delbrueckii, L. bulgaricus (n = 1) [54], L. acidoph-
ilus, B. bifidum, L. fermentum (n = 1) [50], and B. infantis,
B. lactis, L. reuteri (n = 1) which was prepared in probiotic
capsules for human studies and also, oral gavage for animal
studies. The used dosage was 0.6–5 × 108–109 colony-
forming units (CFU) for 22 to 50 days.
Animal studies
Five animal studies were included in the final evaluation
(Table 1). Salehipour et al. [35] investigated the effect of
109 CFU/mL L. plantarum A7, B. animalis and a com-
bination of these probiotics in an experimental model of
MS. They reported that L. plantarum A7 and B. animals
could ameliorate EAE condition through, ameliorated
EAE condition through enhancing the anti-inflammatory
cytokines and cell, such as IL (Interleukin)-10, IL-4, and
TGF-β; T-regs, CD4+, CD25+, and Foxp3+ in spleen
and lymph nodes together with increasing Th2 (T-helper
2) (GATA3); and T-reg (Foxp3) in spleen and brain.
Additionally, a decrease in IL-17, IFN-γ (Interferon
gamma), IL-6, Th1 (T-bet), and Th17 (ROR-γ) have
been observed in all groups. In addition, the lowest level
of inflammation and leukocyte infiltration, demyelin-
ation, and auto reactive T-cells have been reported by a
combination of L. plantarum A7 and B. animalis.
Secher et al. [51] indicated that these beneficial traits
were associated with a decreased secretion of inflammatory
cytokines such as IL-17, IFN-γ, and TNF-α (Tumor Necro-
sis Factor alpha) and an increase in the production of IL-10
as an anti-inflammatory cytokine by autoreactive CD4+ T-
cells, CD4+ Foxp3+ in lymph nodes. Furthermore, these
beneficial traits were reportedly associated with decreasing
the total numbers of CD4+ and MOG-specific CD4+ T-
cells in the SC, in addition to increasing the total numbers
of CD4+ and MOG-specific CD4+ T-cells in inguinal, mes-
enteric, and cervical by 108 CFU/animal E. coli Nissle 1917.
They studied oral administration of the mentioned pro-
biotic strain on infiltration of neuroinflammatory factors
and repaired intestinal barrier dysfunction in male mice of
8 to 12 weeks old, which demonstrated that defect in intes-
tinal barrier function could also be treated with E. coli Nis-
sle 1917 by reducing the FD4 (FITC-Dextran 4 kDa)
passage from the intestinal lumen to the blood.
Kobayashi et al. [52] in their work, indicated that 0.6–
1.2 × 109 CFU/day/mouse L. casei strain Shirota (LcS)
upregulated IL-17 and IFN-γ in ILN cells on days 7 and
12, IL-10, CD4+ CD25+ T-reg cells on day 7, T-reg cells
in the spleen on days 7 and 12. Contrary to this, CD8+
T-cells in the spleen on day 12 decreased in LcS group.
Kwon et al. [53] showed that a mixture of five probio-
tics (IRT5) can ameliorate EAE. Pretreatment and treat-
ment with IRT5 (containing of 108 CFU/g of each strain:
L. casei, L. acidophilus, L. reuteni, B. bifidum, Streptococ-
cus thermophiles) suppressed and delayed EAE onset, re-
spectively. Also, authors elucidated that IRT5 powder
could enhance IL-4, IL-10 in peripheral CD4+ T-cells
and SC, IL-10+ producing CD4+ T-cells in draining
lymph nodes (dLN), IL-2 and IL-10 in dLNs (as a site of
inflammation) at both mRNA and protein level, and
CD4+Foxp3+ T-reg in dLNs. On the other hand, plum-
meting pro-inflammatory cytokines (Th1/Th17; IFN-γ,
TNFα, and IL-17) in peripheral CD4+ T-cells; patho-
genic cytokines such as IL-1β, Th1 type (IL-2, IFN-γ,
and TNFα) and Th17 type (IL-17) in SC; Th1/Th17
polarization, IL-6, IFN-γ, and TNFα at mRNA level in
dLNs; IL-17, IFN-γ, and TNF-α in dLNs at both mRNA
and protein level; infiltration of mononuclear cells into
the SC, Gr1+, or/and CD11b+ monocyte; and CD4+ T-
cells without altering the numbers of B220+ B cells in
the SC have been reported in their study.
Similarly, Lavasani et al. [54] exhibited that each
monostrain probiotic, individually, failed to perform a
therapeutic role in MOG (myelin oligodendrocyte glyco-
protein)-induced EAE in female C57BL/6 mice, and also,
L. paracasei, PCC 101 and L. delbrueckii, DSM 20081
had no effect on the disease development. However, a
mixture of the L. paracasei DSM 13434, L. plantarum
DSM 15312, and L. plantarum DSM 15313 inhibited the
progression of the disease and improved the clinical and
histological signs of EAE in mesenteric lymph nodes
(MLNs), the spleen, and the blood. Moreover, these pro-
biotics established a variety of effects, such as augmenta-
tion of Th2 type cytokines, IL-4, IL-10, TGF-β1, and
shifting cytokine profile from Th1 to Th2 in spleen cell
cultures with L. paracasei DSM 1343 and L. plantarum
DSM 15312, IL-10 by MOG-reactive T-cells in spleen
cells by lacto-mix against control group, IL-10 producing
CD4+T-cells in wild-type (WT) EAE by lacto-mix, IL-27
serum levels in mice fed with L. plantarum DSM 15313.
Despite this, decreasing pro-inflammatory cytokines like
IL-17, TNF-α, and IFN-γ from cells and infiltration of
CD4+ T-cells in CNS tissues by L. paracasei DSM 1343
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and L. plantarum DSM 15312, and lacto-mix have been
elucidated by this group.
Overall, the animal studies well clarified that supple-
mentation with probiotics could leave a major positive
impact on the immune-inflammatory markers, reduce
the severity and progression, and also delay the onset of
the disease. Based on the animal studies’ reports in this
systematic review, it appears that supplementation with
probiotics had a modulating effect on the immune activ-
ity as well as the inflammatory cytokines.
Human studies
The two selected human studies were of significant assess-
ment on the effect of probiotics in MS patients (Table 1).
Kouchaki et al. [50] investigated the clinical and metabolic
response to probiotic supplementation in patients with
MS and exhibited that probiotics could alter hs-CRP levels
in the probiotic group compared to the placebo group.
They demonstrated that B cells’ function was drastically
decreased after 12 weeks of receiving a probiotic capsule
(L. acidophilus, L. casei, B. bifidum and L. fermentum).
In another study, Salami et al. assessed inflammatory bio-
markers before and after 16 weeks of supplementation with
a probiotic capsule comprising B. infantis, B. lactis, L. reu-
teri, L. casei, L. plantarum, and L. fermentum (2 × 109 CFU/
day). Furthermore, they fed the control group with capsules
containing maltodextrine, and the final size of each group
was 24 persons per group. They were able to prove a cru-
cial increase of serum IL-10 level. Contrary to this, the pro-
biotic supplement remarkably decreased IL-6 and hs-CRP
levels. However, no meaningful alteration in TNF-α was
found after adjustment for age and BMI.
Contrary to the animal studies, the number of human
studies were limited; however, according to the evidence
of these two studies, it could be concluded that supple-
mentation with probiotics may have beneficial effects on
the immune function and especially inflammatory pa-
rameters. Nevertheless, more RCTs articles were needed
to reach a rather satisfactory conclusion.
Discussion
In the present systematic review, the effects of several
probiotic supplementations on immune and inflammatory
responses in animal and human models of MS were
surveyed. The majority of the reviewed studies supported
the beneficial effects, including alleviation, prevention, and
delaying the onset of diseases via improving immune and
inflammatory mechanisms (Table 1). Therefore, it seems
that immunological and biological effects of probiotics
through increasing anti-inflammatory cytokines and T-reg
cells, along with reducing pro-inflammatory cytokines, are
the prominent mechanisms that have been demonstrated.
An increase in the incidence and mortality rates related to
MS remains high in the world. On the other hand, taking
probiotic supplements for health and other purposes is
growing. In this review, it was observed that consumption
of probiotics has beneficial effects on systemic and central
inflammation, as well as immune control in EAE models
and MS patients.
Analysis of the method and result sections of the
reviewed articles revealed that 109 CFU/mL dosage was
more effective than other dosages. It is undeniably vital
to note that the type of consumed probiotics species are
of major significance, and the type of strains and host
specificity are the most eminent factors influencing pro-
biotics efficacy [55, 56]. Difference in environmental
conditions and diet could substantially influence the re-
sults of studies. Therefore, it was not feasible to pinpoint
which species could be more effective. However, in two
studies, the effects of several different species on the im-
mune and inflammatory parameters were evaluated [35,
50, 53, 54]. It was suggested that the combination of sev-
eral probiotics has a stronger effect than their separate
use [57, 58].
Another critical point is the duration of the interven-
tions in human and animal reports, which is reported
from 3 to 16 weeks, independent of the dosage and type
of species. This systematic review indicates that the 8–
12-week results were more favorable. Stronger results
were reported within this period. In some cases, im-
provement of physiological responses was observed in 2
or 3 weeks, and favorable results were reported in rela-
tion to immunity and inflammation [59, 60].
Findings from observational studies and published RCTs
suggest that several possible factors are responsible for at-
tenuation of the association between probiotics adminis-
tration and observed MS features. It was a proposed
mechanism related to the effects of probiotics administra-
tion and immune and inflammatory response based on
the included studies in this review (Fig. 2), but further in-
vestigations are still required.
Proposed mechanisms of probiotics in modulating
immune and inflammatory responses
Taken together, animal and human studies present that
probiotics may play an acute role in the modulation of im-
mune and inflammatory mechanisms in MS; however, the
clear mechanisms have not been well defined yet. The ef-
fects of probiotics intake could be confounded by diet [61],
age [62], BMI (body mass index) [63, 64], drugs [65], and
stress [66]. All of these agents hold dire implications for the
gut microbiome composition in addition to host gut func-
tions (permeability and physiology). Evidence has demon-
strated that the use of probiotics could improve the gut
microbial population [21, 67], increasing mucus-secretion
[68], and also prevent the destruction of tight junction pro-
teins (TJs) [69] via a decrease in the amount of lipopolysac-
charides (LPS). When LPS binds to toll-like receptors (TLR
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2, 4) on endothelial cells (ECs), DCs (dendritic cells) and
macrophage cells (MQs) are activated and inflammatory
markers increase [21, 44, 70, 71]. Finally, a reduction of gut
dysbiosis and gut leaky after probiotic therapy could de-
crease the production of inflammatory biomarkers and
blunt excessive immune system stimulation (Fig. 2) [21, 27,
72–74]. Based on the studies cited in this review, differenti-
ation of T-cells toward Th2 and also the production of Th2
cytokines like IL-10 and IL-4 are augmented by probiotics
[53, 54]. Furthermore, another mechanism that can partici-
pate in the progression of EAE is associated with the ex-
pression of transcription factors for Th1 and Th17. Hence,
the administration of probiotics would downregulate these
factors [53]. Furthermore, oral supplementation with pro-
biotics in the EAE model not only provoked the production
of TGF-β and IL-10, but also increased the number of T-
reg cells [44]. In particular, this reaction is simultaneous
with the increasing of Foxp3 [35, 52–54]. Ultimately, it
Fig. 2 Probiotic mechanisms in the gastrointestinal tract. Probiotics administration may manipulate gut microbial composition and reduce
growth of pathogens and stimulate mucin secretion via stimulation of Goblet cells. Probiotic-mediated immunomodulation may occur through
mediation of cytokine secretion through TLRs (ECs, DCs, and MQs), which can also affect proliferation and differentiation of immune cells (T-cells,
CD cells, B cells) especially T-reg cells which resulted in an increase of IL-10 and TGF-β. Also, probiotics, through amplification of TJs, could
improve gut permeability and also decrease entrance of LPS and pathogens from lumen into circulation. T-reg, regulatory T-cell; TLRs, toll-like
receptors; ECs, endothelial cells; DCs, dendritic cells; MQs, macrophage cells; IL, interleukin; CD, cluster of differentiation; TGF-β, transforming
growth factor beta; TNF-α, Tumor necrosis factor alpha; IFN-γ, Interferon gamma; TJPs, tight junction proteins; Ig, immunoglobulin g
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could be demonstrated that an upward trend in the expres-
sion of Foxp3 and GATA3 vs. a downward trend in expres-
sion of T-bet and ROR-γt are the primitive molecular
immunosuppression mechanisms, which regulate the equi-
librium between Th1/Th2 and Th17/T-reg toward a Th2
and T-reg response. However, the authors mentioned that
they would evaluate the role of DCs and epigenetic changes
in both therapeutic and prophylactic models [35, 54]. To be
more precise, the secretion of IFN-γ, IL-17, GM-CSF, and
TNFα was decreased, while the production of IL-10 due to
an enriched population of CD4+CD25+Foxp3+T-regs was
increased. Also, it was verified that oral administration of
probiotics could reduce MOG-reactive T-cell proliferation
and pro-inflammatory cytokine levels and increase IL-10 +
or/and Foxp3+T-reg cells [54].
Limitations
Studies included in this systematic review had several
limitations. (1) The gut microbiome composition has
multiple differences and variations among people and
animals, which may be due to differences in diet, envir-
onmental and personal characteristics, and even genetic
factors, and gut microbiome, in these studies, was not
evaluated directly [29]. (2) The information on the gut
microbiome population is still unclear in diseases [75].
In spite of the remarkable advances in tools and technol-
ogy in bioinformatics, there are still some limitations in
this field. In connection with the identification of pro-
biotics intake on gut-related mechanisms for their ef-
fects, more extensive research is needed [75]. 3) The
effects of the diet on the efficiency of probiotics adminis-
tration as well as gut microbiome composition are very
strong [76, 77]. Therefore, in human studies, attention
to the dietary differences of participants is highly essen-
tial for observing the net outcome of interventions [78].
(4) The use of various drugs, especially antibiotics drugs,
can directly or indirectly affect the gut microbiome,
whose effects in human studies are not well controlled
[79]. Altogether, there were consistent results in human
and animal studies, but the findings of human studies
were likely to be less accurate than animal studies. Some
possible reasons are listed below. Differences in the type
of the parameters in different tissues like brain, SC,
blood, etc.; the various supplemental dosages; type of
species; and samples (gender and age) are due to disrupt
the clear and accurate comparison of the findings among
studies. In addition, human studies were very limited in
this field.
Conclusion
Few investigations have specifically assessed the effect of
probiotic supplements on MS in animals and humans. To
date, interventional studies’ evidences suggest that pro-
biotic supplementation may have beneficial effects on
reducing the risk and preventing and delaying MS. This
paper suggests that administration of probiotics positively
affects CNS disorder and demyelination process, especially
via gut microbiome composition improvements, which is
yet to be investigated. Future studies of probiotic supple-
mentation using particularly large-scale RCTs with ad-
equate dosages and sample sizes in MS are required to
elucidate the potential role of probiotic therapy on promo-
tion of the immune system and suppressing inflammation.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12974-019-1611-4.
Additional file 1. Quality assessment of randomized controlled trials
and animal studies.
Abbreviations
CD: Cluster of differentiation; CFU: Colony-forming unit; CNS: Central nervous
system; EAE: Experimental autoimmune encephalomyelitis;; EDSS: Expanded
disability status scale; GATA3: GATA binding protein 3; GM-CSF: Granulocyte-
macrophage colony-stimulating factor; hs-CRP: High-sensitivity C-reactive
protein; IFN-γ: Interferon gamma; IL: Interleukin; LPS: Lipopolysaccharide;
MLNs: Mesenteric lymph nodes; MOG: Myelin oligodendrocyte glycoprotein;
Multiple Sclerosis (MS); PLP: Proteolipid protein; PRISMA: Preferred Reporting
Items for Systematic Reviews and Meta-Analyses; ROR-γt: RAR-related orphan
receptor gamma; SCFAs: Short-chain fatty acids; TGF-β: Transforming growth
factor beta; Th: T-helper cells; TLRs: Toll-like receptors; TNFα: Tumor necrosis
factor alpha; T-reg: Regulatory T-cell
Acknowledgments
The authors would like to thank Karin Sajtma (UMCG) for his assistance in
designing the search strategy. The efforts and assistance of Erfan Ghasemipour
is also appreciated for his editorial assistance. All authors read and approved
the final manuscript.
Authors’ contributions
MM planned and conceived the study, interpreted the data, and wrote the
manuscript. SM and MM searched the databases and reviewed articles for
inclusion and exclusion criteria. ESH collected the data extracted and
analyzed data. AS were involved in final revising and editing the manuscript.
All authors have given final approval of the version to be published.
Funding
None
Availability of data and materials
All data generated or analyzed during this study are included in this
published article.
Ethics approval and consent to participate
Not applicable
Consent for publication
All the authors agree with the content of this publication.
Competing interests
The authors declare that they have no competing interests.
Author details
1Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz,
Iran. 2Department of Epidemiology, University Medical Center Groningen,
University of Groningen, Groningen 9713, GZ, the Netherlands. 3Neurogenic
Inflammation Research Center, Mashhad University of Medical Sciences,
Mashhad, Iran. 4Biotechnology Research Center, Pharmaceutical Technology
Morshedi et al. Journal of Neuroinflammation          (2019) 16:231 Page 9 of 11
Institute, Mashhad University of Medical Sciences, Mashhad, Iran. 5School of
Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Received: 27 July 2019 Accepted: 3 October 2019
References
1. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara
K, Havrdova E, Hutchinson M, LJAon K. Diagnostic criteria for multiple
Sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–
302.
2. Coyle PKJCLLiN. Symptom management and lifestyle modifications in
multiple Sclerosis. Continuum (Minneap Minn). 2016;22:815–36.
3. Mielcarz DW, Kasper LH. The gut microbiome in multiple sclerosis. Curr
Treat Options Neurol. 2015;17(4):18.
4. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis.
Lancet Neurol. 2008;7(12):1139-51.
5. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the
environment. Autoimmun Rev. 2010;9:A387–94.
6. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk
factors, prodromes, and potential causal pathways. Lancet Neurol. 2010;9:
727–39.
7. Lassmann H. Multiple sclerosis: lessons from molecular neuropathology. Exp
Neurol. 2014;262:2–7.
8. Simons M, Misgeld T, Kerschensteiner M. A unified cell biological
perspective on axon–myelin injury. J Cell Biol. 2014;206:335–45.
9. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis:
pathology of the newly forming lesion. Ann Neurol. 2004;55:458–68.
10. Korn T. Pathophysiology of multiple sclerosis. J Neurol. 2008;255:2–6.
11. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis.
Brain. 2004;127:1463–78.
12. Musette P, Bequet D, Delarbre C, Gachelin G, Kourilsky P, Dormont D. Expansion
of a recurrent V beta 5.3+ T-cell population in newly diagnosed and untreated
HLA-DR2 multiple Sclerosis patients. Proc Natl Acad Sci. 1996;93:12461–6.
13. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan
T, Cua DJ. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and
restrain TH-17 cell–mediated pathology. Nat Immunol. 2007;8:1390–7.
14. Hashemi R, Morshedi M, Jafarabadi MA, Altafi D, Hosseini-Asl SS, Rafie-
Arefhosseini SJNG. Anti-inflammatory effects of dietary vitamin D3 in
patients with multiple Sclerosis. Neurol Genet. 2018;4:e278.
15. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, Miller D,
Waldmann H, Compston A. Monoclonal antibody treatment exposes three
mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol.
1999;46:296–304.
16. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, Ghezzi P.
Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of
experimental autoimmune encephalomyelitis. Brain Res. 2002;952:128–34.
17. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in
the immune and the central nervous system. Br J Pharmacol. 2009;158:
1173–82.
18. Morshedi M, Valenlia KB, Hosseinifard ES, Shahabi P, Abbasi MM, Ghorbani
M, Barzegari A, Sadigh-Eteghad S, Saghafi-Asl M. Beneficial psychological
effects of novel psychobiotics in diabetic rats: the interaction among the
gut, blood, and amygdala. J Nutr Biochem. 2018;57:145–52.
19. Kobayashi T, Kato I, Nanno M, Shida K, Shibuya K, Matsuoka Y, MJI O.
Immunotoxicology: oral administration of probiotic bacteria, Lactobacillus
casei and Bifidobacterium breve, does not exacerbate neurological
symptoms in experimental autoimmune encephalomyelitis. 2010;32:116–24.
20. Kobayashi T, Kato I, Nanno M, Shida K, Shibuya K, Matsuoka Y, Onoue M.
Oral administration of probiotic bacteria, Lactobacillus casei and
Bifidobacterium breve, does not exacerbate neurological symptoms in
experimental autoimmune encephalomyelitis. Immunopharmacology and
immunotoxicology. 2010;32(1):116-24.
21. Hosseinifard E-S, Morshedi M, Bavafa-Valenlia K, Saghafi-Asl M. The novel insight
into anti-inflammatory and anxiolytic effects of psychobiotics in diabetic rats:
possible link between gut microbiota and brain regions. Eur J Nutr. 2019 1-15.
22. Vieira SM, Pagovich OE, Kriegel MA. Diet, microbiota and autoimmune
diseases. Lupus. 2014;23:518–26.
23. Jangi S, Gandhi R, Cox LM, Li N, Von Glehn F, Yan R, Patel B, Mazzola MA,
Liu S, Glanz BL. Alterations of the human gut microbiome in multiple
sclerosis. Nat Commun. 2016;7:12015.
24. Brusca SB, Abramson SB, Scher JU. Microbiome and mucosal inflammation
as extra-articular triggers for rheumatoid arthritis and autoimmunity. Curr
Opin Rheumatol. 2014;26:101.
25. Forbes JD, Van Domselaar G, Bernstein CN. The gut microbiota in immune-
mediated inflammatory diseases. Front Microbiol. 2016;7:1081.
26. Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin
Invest. 2015;125:926.
27. Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell
responses to gut microbiota promote experimental autoimmune
encephalomyelitis. Proc Natl Acad Sci. 2011;108:4615–22.
28. Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner
R, Bencosme Y, Lee YK, Hauser SL. Gut bacteria from multiple sclerosis
patients modulate human T cells and exacerbate symptoms in mouse
models. Proc Natl Acad Sci. 2017;114:10713–8.
29. van den Hoogen WJ, Laman JD, t Hart BA. Modulation of multiple sclerosis
and its animal model experimental autoimmune encephalomyelitis by food
and gut microbiota. Front Immunol. 2017;8:1081.
30. Morshedi M, Valenlia KB, Hosseinifard ES, Shahabi P, Abbasi MM,
Ghorbani M, Barzegari A, Sadigh-Eteghad S, Saghafi-Asl MJTJonb.
Beneficial psychological effects of novel psychobiotics in diabetic rats:
the interaction among the gut, blood, and amygdala. J Nutr Biochem
2018, 57:145–152.
31. Wang J, Tang H, Zhang C, Zhao Y, Derrien M, Rocher E, Vlieg JE-H, Strissel K,
Zhao L, Obin M. Modulation of gut microbiota during probiotic-mediated
attenuation of metabolic syndrome in high fat diet-fed mice. ISME J. 2015;9:1.
32. Choi CH, Chang SK. Alteration of gut microbiota and efficacy of probiotics
in functional constipation. J Neurogastroenterol Motil. 2015;21:4.
33. Ganji- Arjenaki M, Rafieian- Kopaei M. Probiotics are a good choice in
remission of inflammatory bowel diseases: a meta analysis and systematic
review. J Cell Physiol. 2018;233:2091–103.
34. Musa NH, Mani V, Lim SM, Vidyadaran S, Majeed ABA, Ramasamy K.
Lactobacilli-fermented cow's milk attenuated lipopolysaccharide-induced
neuroinflammation and memory impairment in vitro and in vivo. J Dairy
Res. 2017;84:488–95.
35. Salehipour Z, Haghmorad D, Sankian M, Rastin M, Nosratabadi R, Dallal MMS,
Tabasi N, Khazaee M, Nasiraii LR, Mahmoudi M. Bifidobacterium animalis in
combination with human origin of Lactobacillus plantarum ameliorate
neuroinflammation in experimental model of multiple sclerosis by altering
CD4+ T cell subset balance. Biomed Pharmacother. 2017;95:1535–48.
36. Tankou SK, Regev K, Healy BC, Tjon E, Laghi L, Cox LM, Kivisäkk P, Pierre IV,
Hrishikesh L, Gandhi R. A probiotic modulates the microbiome and
immunity in multiple sclerosis. Ann Neurol. 2018;83:1147–61.
37. Kleerebezem M, Vaughan EE. Probiotic and gut lactobacilli and
bifidobacteria: molecular approaches to study diversity and activity. Annu
Rev Microbiol. 2009;63:269–90.
38. Li J, Sung CYJ, Lee N, Ni Y, Pihlajamäki J, Panagiotou G, El-Nezami H.
Probiotics modulated gut microbiota suppresses hepatocellular carcinoma
growth in mice. Proc Natl Acad Sci. 2016;113:E1306–15.
39. Wullt M, Hagslätt M-LJ, Odenholt I, Berggren A. Lactobacillus plantarum 299v
enhances the concentrations of fecal short-chain fatty acids in patients with
recurrent clostridium difficile-associated diarrhea. Dig Dis Sci. 2007;52:2082.
40. Valenlia KB, Morshedi M, Saghafi-Asl M, Shahabi P, Abbasi MMJJoFF: Beneficial
impacts of Lactobacillus plantarum and inulin on hypothalamic levels of
insulin, leptin, and oxidative markers in diabetic rats 2018, 46:529–537.
41. Yadav H, Lee J-H, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of
a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem.
2013;288:25088–97.
42. Valenlia KB, Morshedi M, Saghafi-Asl M, Shahabi P, Abbasi MM. Beneficial
impacts of Lactobacillus plantarum and inulin on hypothalamic levels of insulin,
leptin, and oxidative markers in diabetic rats. J Funct Foods. 2018;46:529-37.
43. Pagnini C, Saeed R, Bamias G, Arseneau KO, Pizarro TT, Cominelli F.
Probiotics promote gut health through stimulation of epithelial innate
immunity. Proc Natl Acad Sci. 2010;107:454–9.
44. Tankou SK, Regev K, Healy BC, Cox LM, Tjon E, Kivisakk P, Vanande IP, Cook
S, Gandhi R, Glanz B. Investigation of probiotics in multiple sclerosis. Mult
Scler J. 2018;24:58–63.
45. Moher D, Liberati A, Tetzlaff J, Altman DGJAoim. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. 2009;151:264–9.
46. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P,
Stewart LA. Preferred reporting items for systematic review and meta-
analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
Morshedi et al. Journal of Neuroinflammation          (2019) 16:231 Page 10 of 11
47. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. Ann Intern
Med. 2009;151(4):264-9.
48. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J,
Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration’s tool for
assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
49. Viswanathan M, Berkman ND, Dryden DM, Hartling L. Assessing risk of bias
and confounding in observational studies of interventions or exposures:
further development of the RTI item bank; 2013.
50. Kouchaki E, Tamtaji OR, Salami M, Bahmani F, Daneshvar Kakhaki R, Akbari E,
et al. Clinical and metabolic response to probiotic supplementation in
patients with multiple sclerosis: a randomized, double-blind, placebo-
controlled trial. Clin Nutr. 2016:1–24.
51. Secher T, Kassem S, Benamar M, Bernard I, Boury M, Barreau F, et al. Oral
administration of the probiotic strain Escherichia coli nissle 1917 reduces
susceptibility to neuroinflammation and repairs experimental autoimmune
encephalomyelitis-induced intestinal barrier dysfunction. Front Immunol.
2017;8:1–10.
52. Kobayashi T, Suzuki T, Kaji R, Serata M, Nagata T, Ando M, et al. Probiotic
upregulation of peripheral IL-17 responses does not exacerbate
neurological symptoms in experimental autoimmune encephalomyelitis
mouse models. Immunopharmacol Immunotoxicol. 2012;34(3):423–33.
53. Kwon HK, Kim GC, Kim Y, Hwang W, Jash A, Sahoo A, et al. Amelioration of
experimental autoimmune encephalomyelitis by probiotic mixture is
mediated by a shift in T helper cell immune response. Clin Immunol. 2013;
146:217–27.
54. Lavasani S, Dzhambazov B, Nouri M, Fak F, Buske S, Molin G, et al. A novel
probiotic mixture exerts a therapeutic effect on experimental autoimmune
encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS
One. 2010;5(2):1–11.
55. Marteau P. Evidence of probiotic strain specificity makes extrapolation of
results impossible from a strain to another, even from the same species.
Ann Gastroenterol Hepatol. 2011;2:1–3.
56. McFarland LV, Evans CT, Goldstein EJ. Strain-specificity and disease-specificity of
probiotic efficacy: a systematic review and meta-analysis. Front Med. 2018;5:124.
57. Kajander K, Myllyluoma E, Rajilić-Stojanović M, Kyrönpalo S, Rasmussen M,
Järvenpää S, Zoetendal E, De Vos W, Vapaatalo H, Korpela R. Clinical trial:
multispecies probiotic supplementation alleviates the symptoms of irritable
bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol
Ther. 2008;27:48–57.
58. Timmerman H, Koning C, Mulder L, Rombouts F, Beynen A. Monostrain,
multistrain and multispecies probiotics—a comparison of functionality and
efficacy. Int J Food Microbiol. 2004;96:219–33.
59. Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis
and insulin resistance by increasing hepatic NKT cells. J Hepatol. 2008;49:
821–30.
60. Patel RM, Myers LS, Kurundkar AR, Maheshwari A, Nusrat A, Lin PW.
Probiotic bacteria induce maturation of intestinal claudin 3 expression and
barrier function. Am J Pathol. 2012;180:626–35.
61. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S,
Collini S, Pieraccini G, Lionetti P. Impact of diet in shaping gut microbiota
revealed by a comparative study in children from Europe and rural Africa.
Proc Natl Acad Sci. 2010;107:14691–6.
62. O'Toole PW, Claesson MJ. Gut microbiota: changes throughout the lifespan
from infancy to elderly. Int Dairy J. 2010;20:281–91.
63. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE,
Sogin ML, Jones WJ, Roe BA, Affourtit JP. A core gut microbiome in obese
and lean twins. Nature. 2009;457:480.
64. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI.
Obesity alters gut microbial ecology. Proc Natl Acad Sci. 2005;102:11070–5.
65. Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. J Clin
Invest. 2014;124:4212–8.
66. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut
microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13:701.
67. Bull-Otterson L, Feng W, Kirpich I, Wang Y, Qin X, Liu Y, Gobejishvili L, Joshi-
Barve S, Ayvaz T, Petrosino J. Metagenomic analyses of alcohol induced
pathogenic alterations in the intestinal microbiome and the effect of
Lactobacillus rhamnosus GG treatment. PLoS One. 2013;8:e53028.
68. Mack D, Ahrné S, Hyde L, slS, Hollingsworth M. Extracellular MUC3 mucin
secretion follows adherence of Lactobacillus strains to intestinal epithelial
cells in vitro. Gut. 2003;52:827–33.
69. Forsyth CB, Farhadi A, Jakate SM, Tang Y, Shaikh M, Keshavarzian A.
Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative
stress, gut leakiness, and liver injury in a rat model of alcoholic
steatohepatitis. Alcohol. 2009;43:163–72.
70. Erridge C, Kennedy S, Spickett CM, Webb DJ. Oxidized phospholipid
inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4
roles for cd14, lps-binding protein, and md2 as targets for specificity of
inhibition. J Biol Chem. 2008;283:24748–59.
71. Guo S, Al-Sadi R, Said HM, Ma TY. Lipopolysaccharide causes an increase in
intestinal tight junction permeability in vitro and in vivo by inducing
enterocyte membrane expression and localization of TLR-4 and CD14. Am J
Pathol. 2013;182:375–87.
72. Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune
and nervous systems in health and disease. Nat Neurosci. 2017;20:145.
73. Thevaranjan N, Puchta A, Schulz C, Naidoo A, Szamosi J, Verschoor CP,
Loukov D, Schenck LP, Jury J, Foley KP. Age-associated microbial dysbiosis
promotes intestinal permeability, systemic inflammation, and macrophage
dysfunction. Cell Host Microbe. 2017;21:455–66 e454.
74. Maldonado Galdeano C, Novotny Nunez I, Carmuega E, de Moreno de
LeBlanc A, Perdigon G. Role of probiotics and functional foods in health:
gut immune stimulation by two probiotic strains and a potential probiotic
yoghurt. Endocr Metab Immune Disord Drug Targets. 2015;15:37–45.
75. Arora T, Bäckhed F. The gut microbiota and metabolic disease: current
understanding and future perspectives. J Intern Med. 2016;280:339–49.
76. Conlon M, Bird A. The impact of diet and lifestyle on gut microbiota and
human health. Nutrients. 2015;7:17–44.
77. Dave M, Higgins PD, Middha S, Rioux KP. The human gut microbiome:
current knowledge, challenges, and future directions. Transl Res. 2012;160:
246–57.
78. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE,
Ling AV, Devlin AS, Varma Y, Fischbach MA. Diet rapidly and reproducibly
alters the human gut microbiome. Nature. 2014;505:559.
79. Devkota S. Prescription drugs obscure microbiome analyses. Science. 2016;
351:452–3.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Morshedi et al. Journal of Neuroinflammation          (2019) 16:231 Page 11 of 11
